|
Lachaine J. Treatment
options for the prevention and treatment of post-operative nausea and vomiting (PONV)
: a pharmacoeconomic review. PharmacoEconomics 2006; 24(10):
Darveau M, Notebaert E,
Denault AY, Williamson D, Albert M, Bélisle S, Lachaine J.
Erythropoietic Response to Two Epoetin alfa Regimens in Critically Ill Patients:
A Pilot Study
Pharmacotherapy 2006; 26(11):
Dobson R, Henry C, Taylor J, Zello G,
Lachaine J, Forbes D, Keegan D
Multidisciplinary teams: attitudes and environmental factors associated with
participation by community pharmacists
Journal of Interprofessional Care. 2006; 20(2):119-132
Lachaine J, Rinfret
S, Merikle E, Tarride J.E.
Persistence and adherence to cholesterol lowering agents.
American Heart Journal. 2006; 152:164-169
Lachaine J, Yelle L, Kaizer L et al.
Quality of life and economic impact of chemotherapy induced
emesis in the context of current practice.
Supportive Cancer Therapy,
2005;2 (3): 181-186.
Lachaine J. Aspects économiques de la
douleur. Frontières, Printemps 2005 : 89-91
Lachaine
J, Crott R. Cost effectiveness of antiemetics use
during cancer chemotherapy. Expert Review of Pharmacoeconomics & Outcomes
Research. 2003 ; 3(3) : 89-98
Darveau M,
Lachaine J. Appréciation critique d’une analyse coût-efficacité :
Utilisation de la protéine C activée (drotrecogin alfa) pour le sepsis sévère.
Pharmactuel 2003 ; 36 (2) :62-67
Lachaine J.
Chemotherapy-induced emesis: treatment options. Hospital Pharmacy Europe. Summer
2003 :2-3
Lesk M, Lachaine J. Medical therapy of glaucoma: Focus
on newer agents. Ophthalmic Practice. 2003; 21(2) :1-7
Lachaine
J, Laurier C, Contandriopoulos A-P. Monetary value of
quality of life improvements. PharmacoEconomics, 2003; 21(12) :865-874.
Lachaine J, Laurier C.
Cost-efficacy analysis of ondansetron regimens for control of emesis induced by
noncisplatin, moderately emetogenic chemotherapy. American Journal of
Health-System Pharmacy. 2002; 59 :1837-1846
Lachaine J, Laurier C, Economic
evaluation of the modalities of administration of ondansetron for the control of
chemotherapy induced emesis.
American Journal of Health-System Pharmacy. 2002;
59 :1837-1846
Lachaine J, Valiquette L, Crott
R. Economic evaluation of NMP22 in the management of bladder cancer. Canadian
Journal of Urology. 2000;7(2):974-980
Lachaine J, Laurier C,
Langleben A, Vaillant L. Cost-effectiveness and quality of life of ondansetron
and metoclopramide for moderately emetogenic chemotherapy regimens in breast
cancer. Critical Reviews in Oncology/Hematology.
1999;32:105-112
Lachaine
J, Crott R. Comment construire et utiliser un arbre de décision dans une
évaluation économique. Actualité Médicale. 1999; 20(24) : 22-23
Lachaine
J, Rousseau L. Comment apprécier les avantages d’une intervention de santé?
La mesure de l’efficacité. Actualité Médicale. 1999; 19(42) : 30-31
Lachaine
J, Crott R. Comment mettre en relation les coûts et les résultats des
interventions. Actualité Médicale. 1999; 20(15) : 40-41
Bussières
JF, Lachaine J. Les différentes facettes du per-diem hospitalier.
Quebec pharmacie. 1999; 46(6) :560-564
Laurier C, Lachaine J, Ducharme M. Economic evaluation
of antibacterials in the treatment of acute sinusitis. Pharmacoeconomics,
1999;15(1) : 97-113
Crott R,
Lachaine J. Comment apprécier les coûts d’une intervention.
Actualité Médicale. 1998; 19(40) : 42-43
Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier
G. Economic Evaluation of Zuclopenthixol Acetate Compared with Injectable
Haloperidol in Schizophrenic Patients with Acute Psychosis. Clinical
Therapeutics, 1997 ; 19(2) : 316-329
|
